You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

High%20Risk%20Multiple%20Myeloma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma Trial in Houston (Isatuximab, lenalidomide)

Not yet recruiting
  • Multiple Myeloma
  • Houston, Texas
    M D Anderson Cancer Center
Mar 8, 2023

Multiple Myeloma Trial in Hangzhou (Ixazomib plus low-dose lenalidomide, Ixazomib)

Recruiting
  • Multiple Myeloma
  • Ixazomib plus low-dose lenalidomide
  • Ixazomib
  • Hangzhou, Zhejiang, China
    Yang Xu
Feb 9, 2023

Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma Trial in Wuhan (Daratumumab, Carfilzomib,

Recruiting
  • Multiple Myeloma
  • +2 more
  • Wuhan, Hubei, China
    Institute of Hematology, Union Hospital, Tongji Medical College,
Nov 18, 2023

Multiple Myeloma, High-Risk Cancer Trial in Montreal (Bortezomib following nonmyeloablative allogeneic transplant)

Active, not recruiting
  • Multiple Myeloma
  • High-Risk Cancer
  • Bortezomib following nonmyeloablative allogeneic transplant
  • Montreal, Quebec, Canada
    Hôpital Maisonneuve-Rosemont
Aug 22, 2022

Multiple Myeloma Trial in Tianjin (Autologous hematopoietic stem cell transplantation, C-CAR088)

Recruiting
  • Multiple Myeloma
  • Autologous hematopoietic stem cell transplantation
  • C-CAR088
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Nov 21, 2022

High-Risk de Novo Multiple Myeloma Trial in Spain (Daratumumab, Bortezomib, Lenalidomide)

Not yet recruiting
  • High-Risk de Novo Multiple Myeloma
  • Badalona, Spain
  • +9 more
Apr 27, 2023

Multiple Myeloma Trial in Philadelphia (BCMA CART + huCART19, CART BCMA or CART BCMA + huCART19, Single-dose infusion of CART

Active, not recruiting
  • Multiple Myeloma
  • BCMA CART + huCART19
  • +2 more
  • Philadelphia, Pennsylvania
    Univ. of Pennsylvania
Jul 11, 2022

Multiple Myeloma Trial in Philadelphia (CART-19 cells)

Terminated
Has Results
  • Multiple Myeloma
  • CART-19 cells
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Jan 4, 2023

Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM) Trial (Linvoseltamab)

Not yet recruiting
  • Monoclonal Gammopathy of Undetermined Significance (MGUS)
  • Smoldering Multiple Myeloma (SMM)
  • (no location specified)
Nov 17, 2023

Myeloma Multiple Trial in Orange, Nashville (Descartes 08)

Recruiting
  • Myeloma Multiple
  • Descartes 08
  • Orange, California
  • +1 more
Apr 4, 2022

Smoldering Multiple Myeloma (SMM) Trial (Linvoseltamab)

Not yet recruiting
  • Smoldering Multiple Myeloma (SMM)
  • (no location specified)
Jul 13, 2023

Multiple Myeloma Trial in Miami (Teclistamab, Talquetamab, Daratumumab SC)

Not yet recruiting
  • Multiple Myeloma
  • Miami, Florida
    University of Miami
Oct 20, 2023

Myeloma Multiple Trial in United States (Descartes 11)

Completed
  • Myeloma Multiple
  • Descartes 11
  • Bethesda, Maryland
  • +3 more
Mar 10, 2022

Smoldering Multiple Myeloma Trial (Selinexor)

Not yet recruiting
  • Smoldering Multiple Myeloma
  • (no location specified)
Oct 27, 2022

Multiple Myeloma Trial in Montréal (ECT-001 (UM171) expanded cord blood)

Active, not recruiting
  • Multiple Myeloma
  • ECT-001 (UM171) expanded cord blood
  • Montréal, Quebec, Canada
    CIUSSS de l'Est-de-l'île-de-Montréal, Installation Hôpital Maiso
Mar 8, 2022

Multiple Myeloma, Smoldering Multiple Myeloma Trial in Oslo (TG01)

Not yet recruiting
  • Multiple Myeloma
  • Smoldering Multiple Myeloma
  • TG01
  • Oslo, Norway
    Oslo Myeloma Center
May 2, 2023

Multiple Myeloma Trial in Hefei, Changzhou, Nanjing (Fully human BCMA chimeric antigen receptor autologous T cell injection

Not yet recruiting
  • Multiple Myeloma
  • Fully human BCMA chimeric antigen receptor autologous T cell injection (CT103A)
  • Hefei, Anhui, China
  • +3 more
Jan 3, 2022

Multiple Myeloma Trial run by the National Cancer Institute (NCI) (Dexamethasone, Carfilzomib, Daratumumab)

Recruiting
  • Multiple Myeloma
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

High-risk Smoldering Multiple Myeloma, Smoldering Multiple Myeloma, Multiple Myeloma Trial in Boston (Teclistamab, Lenalidomide,

Recruiting
  • High-risk Smoldering Multiple Myeloma
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Aug 11, 2022

Multiple Myeloma Trial in Hackensack (Pembrolizumab, Lenalidomide, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Hackensack, New Jersey
    John Theurer Cancer Center-Hackensack Meridian Health
Jan 18, 2022

Multiple Myeloma Trial in United States (Elotuzumab, Pomalidomide, Carfilzomib)

Terminated
  • Multiple Myeloma
  • Encinitas, California
  • +5 more
Mar 15, 2022

Multiple Myeloma, High Risk Smoldering Multiple Myeloma Trial in United States (Ixazomib (MLN9708), Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • High Risk Smoldering Multiple Myeloma
  • Basking Ridge, New Jersey
  • +5 more
Nov 15, 2022

ISS Stage III Plasma Cell Myeloma, Plasma Cell Myeloma Trial in Rochester (procedure, drug, biological)

Not yet recruiting
  • ISS Stage III Plasma Cell Myeloma
  • Plasma Cell Myeloma
  • Bone Marrow Aspiration and Biopsy
  • +7 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Aug 9, 2022

Multiple Myeloma, Smoldering Multiple Myeloma Trial in Boston (Ciltacabtagene Autoleucel, Cyclophosphamide, Fludarabine

Not yet recruiting
  • Multiple Myeloma
  • Smoldering Multiple Myeloma
  • Ciltacabtagene Autoleucel
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Mar 2, 2023

Multiple Myeloma, Cancer, Hematologic Cancer Trial in Cork (Discontinuation of maintenance treatment)

Not yet recruiting
  • Multiple Myeloma
  • +2 more
  • Discontinuation of maintenance treatment
  • Cork, Ireland
    Cork University Hospital
May 10, 2023